Treating TBI mice with cis mAb inhibits cistauosis, prevents tauopathy development and spread of cis P-tau to other neurons, and restores TBI-associated consequent structural and functional abnormalities seen even in humans [36,190]. Here, MAPT is linked to tauopathy.